Completed PHASE2 INTERVENTIONAL 7-arm NCT01147744

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma While Treated With Short Acting Beta2-agonist.

Sponsor: GlaxoSmithKline

Conditions Asthma

Interventions Fluticasone Propionate 100mcg via ACCUHALER/DISKUS GSK2190915 100mg GSK2190915 10mg GSK2190915 300mg GSK2190915 30mg Montelukast 10mg Placebo GSK2190915 one tablet Placebo GSK2190915 two tablets Placebo fluticasone propionate via ACCUHALER/DISKUS Placebo montelukast

Updated 9 times since 2017 Last updated: Sep 28, 2017 Started: Jun 28, 2010 Primary completion: Oct 6, 2011 Completion: Oct 6, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Asthma, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE2
Sep 2017 — Oct 2017 [monthly]

Completed PHASE2
Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bangor, United States , Bellingham, United States , Bialystok, Poland , Birmingham, United States , Brasov, Romania , Bucharest, Romania , Canton, United States , Chiba, Japan , Cluj-Napoca, Romania , Columbia, United States and 48 more locations